Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 008064206 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Fairmount Funds Management LLC
13D/A
|
20.0% |
6/9/2026
Event 6/5/2026
|
||
| Fairmount Funds Management LLC | 20.0% | |||
| Fairmount Healthcare Fund II L.P. | 16.2% | |||
| Fairmount Healthcare Co-Invest IV L.P. | 4.4% | |||
| Peter Evan Harwin | 20.0% | |||
| Tomas Kiselak | 20.0% | |||
|
FMR LLC
13G
|
14.7% |
6/6/2025
Event 5/30/2025
|
||
| FMR LLC | 14.7% | |||
| Abigail P. Johnson | 14.7% | |||
| Janus Henderson Group Ltd. 13G/A | 10.6% |
7/8/2026
Event 6/30/2026
|
||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
8.3% |
8/14/2026
Event 6/30/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 8.3% | |||
| VHCP Co-Investment Holdings III, LLC | 8.3% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 8.3% | |||
| VHCP Management III, LLC | 8.3% | |||
| VHCP Management EG, LLC | 8.3% | |||
| Nimish Shah | 8.3% | |||
| Bong Y. Koh | 8.3% | |||
|
RA Capital Management, L.P.
13G
|
7.0% |
10/16/2025
Event 10/8/2025
|
||
| RA Capital Management, L.P. | 7.0% | |||
| Peter Kolchinsky | 7.0% | |||
| Rajeev Shah | 7.0% | |||
| RA Capital Healthcare Fund, L.P. | 7.0% | |||
|
Paradigm Biocapital Advisors LP
13G
|
5.1% |
7/17/2026
Event 7/10/2026
|
||
| Paradigm BioCapital Advisors LP | 5.1% | |||
| Paradigm BioCapital Advisors GP LLC | 5.1% | |||
| Senai Asefaw, M.D. | 5.1% | |||
| Paradigm BioCapital International Fund Ltd. | 4.5% | |||
|
Bellevue Group AG
13G/A
|
5.0% |
8/14/2026
Event 6/30/2026
|
||
| Bellevue Group AG | 5.0% | |||
| Bellevue Asset Management AG | 5.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (7) | ||||
| BlackRock, Inc. 13G/A | 4.7% |
4/27/2026
Event 3/31/2026
|
||
| Vanguard Group Inc 13G/A | 4.2% |
1/30/2026
Event 12/31/2025
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
4.2% |
11/14/2025
Event 9/30/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | |||
| FHMLSP, L.P. | 4.2% | |||
| FHMLSP, L.L.C. | 4.2% | |||
| Frazier Life Sciences X, L.P. | 0% | |||
| FHMLS X, L.P. | 0% | |||
| FHMLS X, L.L.C. | 0% | |||
| Frazier Life Sciences XI, L.P. | 0.1% | |||
| FHMLS XI, L.P. | 0.1% | |||
| FHMLS XI, L.L.C. | 0.1% | |||
| James N. Topper | 0% | |||
| Patrick J. Heron | 0% | |||
|
Sofinnova Venture Partners X, L.P.
13D/A
|
0.3% |
3/5/2026
Event 4/28/2025
|
||
| Sofinnova Venture Partners X, L.P. ("SVP X") | 0.3% | |||
| Sofinnova Management X, L.P. ("SM X LP") | 0.3% | |||
| Sofinnova Management X-A, L.L.C. ("SM X LLC") | 0.3% | |||
| Dr. James I. Healy ("Healy") | 0.3% | |||
| Dr. Maha Katabi ("Katabi") | 0.3% | |||
|
TCG Crossover GP I, LLC
13G/A
|
0.2% |
5/15/2025
Event 4/28/2025
|
||
| TCG Crossover GP I, LLC | 0.2% | |||
| TCG Crossover Fund I, L.P. | 0.2% | |||
| Chen Yu | 0.2% | |||
|
Atlas Venture Fund XII, L.P.
13D/A
|
0.2% |
4/30/2025
Event 4/28/2025
|
||
| Atlas Venture Fund XII, L.P. | 0.2% | |||
| Atlas Venture Associates XII, L.P. | 0.2% | |||
| Atlas Venture Associates XII, LLC | 0.2% | |||
|
Deep Track Capital, LP
13G/A
|
0% |
2/13/2026
Event 12/31/2025
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||